These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25810706)

  • 21. A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.
    Krystal J; Hanson D; Donnelly D; Atlas M
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30874. PubMed ID: 38234020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.
    Mayer T; Lacy J; Baehring J
    Clin Med Oncol; 2008; 2():455-9. PubMed ID: 21892317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease progression patterns of bevacizumab responders with recurrent malignant gliomas.
    Kim JH; Jung TY; Hwang EC; Jung SH; Jung S; Kim IY; Jang WY; Moon KS; Lee KH; Kim SK
    Oncol Lett; 2017 Sep; 14(3):3529-3535. PubMed ID: 28927109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
    Odia Y; Iwamoto FM; Moustakas A; Fraum TJ; Salgado CA; Li A; Kreisl TN; Sul J; Butman JA; Fine HA
    J Neurooncol; 2016 Mar; 127(1):127-35. PubMed ID: 26643807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Musa F; Pothuri B; Blank SV; Ling HT; Speyer JL; Curtin J; Boyd L; Li X; Goldberg JD; Muggia F; Tiersten A
    Gynecol Oncol; 2017 Feb; 144(2):279-284. PubMed ID: 27931751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
    Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
    Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Taillibert S; Vincent LA; Granger B; Marie Y; Carpentier C; Guillevin R; Bellanger A; Mokhtari K; Rousseau A; Psimaras D; Dehais C; Sierra del Rio M; Meng Y; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2009 May; 72(18):1601-6. PubMed ID: 19414728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
    Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WKA; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
    J Clin Oncol; 2023 Nov; 41(32):4945-4952. PubMed ID: 37935104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
    Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
    J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
    Mantica M; Pritchard A; Lieberman F; Drappatz J
    J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
    Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
    J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.